Jan Elsner

This inventor holds 22 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Chemistry. Top assignee: Signal Pharmaceuticals, Inc.. Active years: 2012-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jan Elsner. Retrieved from https://idiyas.com/inventor/jan-elsner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 9 (Patent Applications = 10)

Average Co-Inventor Count = 14.9

ph-index = 7

Forward Citations = 207(Granted Patents)

Location History:

San Diego, CA (US) (2012 - 2017)
Solana Beach, CA (US) (2017 - 2022)

Company Filing History:

22 out of 169

Signal Pharmaceuticals, Inc.

patents

Years Active: 2012-2024

Loading Chart...

Areas of Expertise:

mTOR Kinase Inhibitors

Pyrimidines

Heteroaryl Compounds

Pyrazines

Diaminocarboxamides

Pyrrolopyrimidines

Oncology Treatments

Synthesis Methods

Compositions

Pharmaceuticals

Chemical Compounds

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12129237 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2024-10-29),

2. 11325890 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2022-05-10),

3. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),

4. 10919865 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2021-02-16),

5. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),

6. 10266500 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2019-04-23),

7. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),

8. 10040770 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2018-08-07),

9. 9795607 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2017-10-24),

10. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2017-09-26),

11. 9701643 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2017-07-11),

12. 9428509 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2016-08-30),

13. 9346812 - Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith (2016-05-24),

14. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors (2015-11-24),

15. 9139534 - Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith (2015-09-22),

Title: Jan Elsner: Innovator in Pharmaceutical Chemistry

Introduction: Jan Elsner, based in San Diego, CA, is a prominent inventor in the field of pharmaceutical chemistry. With a remarkable portfolio of 22 patents, he has made significant contributions to the development of innovative compounds and treatments. His work focuses on creating novel diaminopyrimidine compounds that have potential applications in various therapeutic areas.

Latest Patents: Among Jan's most recent patents are the "Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith". This patent showcases his expertise in designing valuable compounds with specific structural properties that can be leveraged for treatment methodologies.

Career Highlights: Jan has built his career at Signal Pharmaceuticals, Inc., where he continues to drive innovation in drug development. His extensive research and contributions to the pharmaceutical industry have established him as a key player in the field.

Collaborations: Throughout his career, Jan has worked alongside esteemed colleagues, including Jennifer Riggs and Roy Leonard Harris, III. These collaborations have fostered a dynamic environment that has led to groundbreaking advancements and a deeper understanding of pharmaceutical compounds.

Conclusion: Jan Elsner epitomizes the spirit of innovation within the pharmaceutical industry. His numerous patents and collaborations highlight his commitment to advancing therapeutic solutions and improving healthcare outcomes. As he continues to push the boundaries of pharmaceutical chemistry, Jan remains a vital asset to Signal Pharmaceuticals, Inc. and the wider scientific community.

Profile summary based on public USPTO records.